Filing Flows › Xenetic Biosciences (XBIO) › Q1 2026
Xenetic Biosciences (XBIO) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
Xenetic Biosciences (XBIO) reported revenue of $807K for the first quarter 2026 (Q1 2026), +36% from a year earlier and +5% from the quarter before. Operating margin was -62.2%, net loss $456K (56.6% of revenue).
Xenetic Biosciences, Q1 2026: revenue $807K (+36% year over year), operating margin -62.2%, net loss $456K, operating cash flow −$536K. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $807K | +5% | +36% |
| Operating profit | −$502K | — | — |
| Net earnings | −$456K | — | — |
| Operating cash flow | −$536K | — | — |
What changed
Revenue was $807K in Q1 2026, up 36% year over year and up 5% from the previous quarter.
Operating costs exceeded revenue by $502K, an operating margin of -62.2%. Total costs fell 15% while revenue rose 36%. The quarter ended with a net loss of $456K, narrower than the previous quarter's $579K loss.
Operating cash flow was −$536K. Non-cash charges added back $11K of share-based compensation. Working capital and other items used $91K.
Questions
What was Xenetic Biosciences' revenue in the first quarter 2026?
Xenetic Biosciences (XBIO) reported revenue of $807K for the first quarter 2026 (Q1 2026), +36% from a year earlier and +5% from the quarter before.
Was Xenetic Biosciences profitable in the first quarter 2026?
Operating loss was $502K (-62.2% of revenue) and net loss $456K.